NINDS is offering Phase IIB Renewal Awards to bridge the substantial ‘Valley of Death’ funding gap for medical biotechnology products. This grant is designed for previously funded SBIR/STTR Phase II projects, enabling them to achieve critical milestones for commercialization. It supports innovations requiring Federal regulatory approval or complex research tools nearing market readiness. NINDS encourages awardees to secure independent third-party funding and foster strategic partnerships with investors, facilitating a seamless transition from pre-clinical research to market.
Opportunity ID: 331090
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-21-114 |
| Funding Opportunity Title: | NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jan 25, 2021 |
| Last Updated Date: | Jan 05, 2024 |
| Original Closing Date for Applications: | Jan 05, 2024 |
| Current Closing Date for Applications: | Apr 05, 2024 |
| Archive Date: | May 05, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-21-114.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| updated expiration date as per NOT-NS-24-051 | Jan 05, 2024 | |
| Jan 25, 2021 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-21-114 |
| Funding Opportunity Title: | NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jan 25, 2021 |
| Last Updated Date: | Jan 05, 2024 |
| Original Closing Date for Applications: | Jan 05, 2024 |
| Current Closing Date for Applications: | Apr 05, 2024 |
| Archive Date: | May 05, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-21-114.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-21-114 |
| Funding Opportunity Title: | NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 25, 2021 |
| Last Updated Date: | Jan 25, 2021 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jan 05, 2024 |
| Archive Date: | Feb 10, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-21-114.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
Folder 331090 Full Announcement-PAR-21-114 -> PAR-21-114-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00265169 | Mar 05, 2021 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00270906 | Dec 16, 2021 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278341 | Nov 14, 2022 | Apr 05, 2024 | View |
Package 1
Mandatory forms
331090 RR_SF424_2_0-2.0.pdf
331090 PHS398_CoverPageSupplement_5_0-5.0.pdf
331090 RR_OtherProjectInfo_1_4-1.4.pdf
331090 PerformanceSite_2_0-2.0.pdf
331090 RR_KeyPersonExpanded_2_0-2.0.pdf
331090 RR_Budget_1_4-1.4.pdf
331090 PHS398_ResearchPlan_4_0-4.0.pdf
331090 SBIR_STTR_Information_1_3-1.3.pdf
331090 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
331090 RR_SubawardBudget30_1_4-1.4.pdf
331090 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
331090 RR_SF424_5_0-5.0.pdf
331090 PHS398_CoverPageSupplement_5_0-5.0.pdf
331090 RR_OtherProjectInfo_1_4-1.4.pdf
331090 PerformanceSite_4_0-4.0.pdf
331090 RR_KeyPersonExpanded_4_0-4.0.pdf
331090 RR_Budget_3_0-3.0.pdf
331090 PHS398_ResearchPlan_4_0-4.0.pdf
331090 SBIR_STTR_Information_3_0-3.0.pdf
331090 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
331090 RR_SubawardBudget30_3_0-3.0.pdf
331090 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
331090 RR_SF424_5_0-5.0.pdf
331090 PHS398_CoverPageSupplement_5_0-5.0.pdf
331090 RR_OtherProjectInfo_1_4-1.4.pdf
331090 PerformanceSite_4_0-4.0.pdf
331090 RR_KeyPersonExpanded_4_0-4.0.pdf
331090 RR_Budget_3_0-3.0.pdf
331090 PHS398_ResearchPlan_5_0-5.0.pdf
331090 SBIR_STTR_Information_3_0-3.0.pdf
331090 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
331090 RR_SubawardBudget30_3_0-3.0.pdf
331090 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
